

## EXHIBIT B

**Exhibit 3**  
**Percentage "Spreads"<sup>1,2</sup> between AWP and AMP**  
**Branded Products Accused in New York Counties<sup>3</sup>**  
**1997 - 2005**

Brand Name	9-Digit NDC	Date Added to First DataBank	Date of First Gross Sales	Date of Last Gross Sales	(Percent)										
					1997	1998	1999	2000	2001	2002	2003	2004	2005		
(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)	(j)	(k)	(l)	(m)	(n)		
Celestone Schupan	000850566	01/01/82	01/01/91	09/30/07	25.0	25.6	25.4	30.3	24.3	24.6	30.6				
Claritin	000850458	04/14/93	04/03/07	04/03/07	23.2	22.9	22.8	23.7	24.7						
Claritin	000850612	10/15/96	10/14/96	04/23/01	23.4	22.8									
Claritin	000851128	02/06/97	02/24/97	01/29/07	23.0	22.7	22.7	23.2	24.8						
Claritin	000851223	05/25/99	04/20/99	04/03/07		22.7	22.7	23.4	25.0						
Claritin-D	000850635	11/15/94	11/14/94	08/07/07	23.4	23.0	22.8	23.2	25.4						
Claritin-D	000851233	12/07/98	12/01/98	01/31/04			22.6	23.2	25.2	29.3	31.9	40.8	37.3		
Diprolene	000850575	03/19/87	01/01/91	09/27/07	26.8	26.3	26.5	27.4	28.1	29.3	34.8	63.1	32.5		
Diprolene	000850517	08/07/83	01/01/91	09/27/07	25.7	25.5	24.4	26.4	27.1	32.2	33.2				
Diprolene	000850634	12/05/91	12/01/91	12/20/06	27.4	27.7	27.7	28.5	29.9	32.2	29.4	29.3	29.5		
Diprolene	000850962	05/19/88	01/01/91	09/27/07	22.9	22.7	22.8	23.5	24.2	24.1	29.8	38.0	35.1		
Elocon	000850370	07/02/87	01/01/91	09/26/07	29.5	29.2	29.4	29.5	31.8	32.4	36.2	36.9	35.8		
Elocon	000850567	07/02/87	01/01/91	09/30/07	29.9	29.4	29.8	29.5	30.7	32.4	36.2	36.9	35.8		
Elocon	000850854	05/04/89	01/01/91	09/26/07	22.9	22.7	22.8	23.4	24.4	24.4	32.1	30.5	28.9		
Estinyl	000850070	01/01/82	01/01/97	03/07/02	24.5	25.6	23.8	23.8	25.0	29.0	27.2	27.7			
Estinyl	000850525	02/09/89	01/01/91	04/03/07	23.2	22.8	23.0	24.5	25.4	27.9	33.7	28.4	34.2		
Indur	000851153	05/05/95	05/10/95	11/07/06	22.7	23.1	23.7	29.4	36.7	27.9	28.5	29.7	29.7		
Indur	000853306	12/26/95	01/09/96	12/20/06	22.7	22.9	24.8	35.3	48.2	22.6	28.5	29.7			
Intron A	000850285	06/12/86	01/01/91	01/07/04	22.8	22.8	22.7	24.9	23.3	23.3	28.0	30.1	29.5		
Intron A	000850539	12/01/88	01/01/91	09/27/07	23.0	22.5	22.6	25.0	23.9	26.2	28.2	29.9	29.6		
Intron A	000850371	06/12/86	01/01/91	09/28/07	19.9	24.4	23.0	25.5	23.9						
Intron A	000850647	01/03/91	03/04/91	11/08/02	26.9	22.7	23.3	25.1	22.9	26.0	28.8	30.1	29.5		
Intron A	000851110	12/19/95	12/06/95	09/26/07	22.6	22.7	22.7	25.2	24.2	25.6	28.3	32.0	29.5		
Intron A	000851133	01/30/97	02/04/97	09/27/07	23.3	83.3	82.2	25.2	24.2	25.5	29.3	30.3	29.5		
Intron A	000851168	01/30/97	02/04/97	09/27/07	22.6	22.8	22.8	25.2	24.6	25.5	29.3	30.3	29.5		
Intron A	000851179	01/30/97	02/03/97	09/05/07	22.4	22.6	22.5	25.3	23.7	22.5	28.6	32.7	29.6		
Intron A	000851191	01/30/97	02/03/97	12/12/02	22.6	22.7	22.6	25.4	22.8	22.6					
Intron A	000851235	07/14/98	07/07/98	09/27/07			22.8	25.3	24.3	25.1	28.9	30.2	29.5		
Intron A	000851242	07/14/98	07/07/98	09/27/07			22.9	25.7	24.4	24.4	28.5	29.8	29.6		
Intron A	000851254	07/14/98	07/07/98	09/26/07			22.7	25.0	24.7	24.9	28.5	30.2	29.7		
K-Dur	000850263	01/22/87	01/01/91	09/05/07	23.0	22.9	22.6	24.5	25.5	24.5	23.9	30.0	29.3		
K-Dur	000850787	01/22/87	01/01/91	09/05/07	23.5	23.0	22.9	24.5	25.5	27.6	37.6	30.2	30.0		
Loramin	000850182	01/01/82	01/01/91	12/11/02	12.8	14.0	4.8	3.9	4.1						
Loramin	000850613	01/01/82	01/01/91	10/09/02	51.7	52.4	54.1	56.8	42.7						
Lorison	000850869	01/03/01	12/12/00	09/25/07					33.9	44.5	28.3	31.3	30.6		
Lorison	000850924	07/01/84	01/01/91	09/27/07	25.2	24.9	24.9	26.4	25.0	29.7	27.8	30.0			
Nasonex	000851197	10/16/97	10/14/97	03/21/07	25.3	31.3	26.0	26.3	29.8	31.5	30.5	36.6	42.8		
Niro-Dur	000850819	03/31/94	03/22/94	09/28/07	26.7	37.3	31.2	28.4	33.9	34.4	32.5	75.5	50.0		
Niro-Dur	000853305	01/29/87	01/01/91	09/27/07				27.7	34.5	34.0	31.2	50.2	60.3		
Niro-Dur	000853310	01/29/87	01/01/91	09/26/07	26.4	30.5	26.8	27.9	31.4	34.8	32.6	61.6	43.1		
Niro-Dur	000853315	01/29/87	01/01/91	09/27/07	26.4	30.5	26.8	27.9	31.5	32.5	31.2	49.2	96.1		
Niro-Dur	000853320	01/29/87	01/01/91	09/27/07	26.3	29.5	26.2	27.0	31.8	32.7	30.6	45.1	73.5		
Niro-Dur	000853330	01/29/87	01/01/91	09/26/07	31.7	30.4	30.3	29.3	27.7						
Normadyne	000850752	08/24/84	01/01/91	02/08/02	38.1	37.3	35.2	35.1	22.7	27.3	29.7	32.0	32.3		
Peg-Intron	000851279	01/31/01	02/06/01	09/28/07					22.6	27.1	29.8	31.3	31.3		
Peg-Intron	000851291	01/31/01	02/06/01	09/26/07					23.0	27.1	29.6	31.7	31.1		
Peg-Intron	000851304	01/31/01	02/06/01	09/27/07					22.8						
Peg-Intron	000851316	02/02/04	02/10/04	09/27/07											
Peg-Intron	000851323	02/02/04	02/11/04	09/27/07											
Peg-Intron	000851468	01/31/01	02/06/01	09/27/07											
Peg-Intron	000851370	02/02/04	02/16/04	09/27/07											

**Exhibit 3**  
**Percentage "Spreads"<sup>1,2</sup> between AWP and AMP**  
**Branded Products Accused in New York Counties<sup>3</sup>**  
**1997 - 2005**

Brand Name	9-Digit NDC	Date Added to First DataBank	Date of First Gross Sales	Date of Last Gross Sales	1997	1998	1999	2000	(Percent)					2004	2005
					(f)	(g)	(h)	(i)	(j)	(k)	(l)	(m)	(n)		
Permitil	000850296	01/01/82	01/02/97	03/30/00	23.1	23.2	23.4								
Proventil	000850208	02/19/87	01/01/91	03/30/03	40.6	27.7	24.4	29.3	30.5	42.1					
Proventil	000850209	02/19/87	01/01/91	10/18/02	53.1	27.2	24.2	25.7	40.5	29.6					
Proventil	000850431	06/25/87	01/01/91	04/22/02	23.2	22.7	22.3	23.6	24.7						
Proventil	000850614	01/01/82	01/01/91	09/27/07	27.5	23.9	23.6	24.1	23.4	29.7	28.5	29.3	31.6		
Proventil	000851132	10/16/96	12/16/96	09/30/07	37.7	28.0	23.1	23.9	40.9	30.9	27.6	29.3	30.4		
Rebetron	000851236	06/11/98	06/08/98	11/30/04			24.0	26.3	26.3	17.0	22.1	26.9			
Rebetron	000851241	06/11/98	06/08/98	05/08/03			26.7	28.2	28.7	27.4					
Rebetron	000851258	07/14/98	07/07/98	03/15/05			28.0	29.9	30.6	28.0	26.1	33.5			
Tenodur	000851244	08/19/99	08/23/99	09/19/07				22.8	24.5	30.2	28.2	31.0	29.1		
Tenodur	000851248	08/19/99	08/23/99	09/28/07				22.8	24.5	30.3	28.4	29.9	29.1		
Tenodur	000851252	08/19/99	08/23/99	09/10/07				22.8	24.5	29.6	28.4	30.2	29.5		
Tenodur	000851259	08/19/99	08/23/99	08/27/07				22.9	24.4	29.6	28.5	30.2	29.0		
Theco-Dur	000850584	01/22/87	01/01/91	02/17/02	43.4	32.8	34.8	34.0							
Trilafon	000850012	01/01/82	01/02/97	09/16/02	27.1	29.0	28.2	31.8	35.0						
Trilafon	000850363	01/01/82	01/01/97	05/17/00	22.6	23.7	22.5								
Vancense	000850041	01/01/82	01/01/91	01/26/01	21.8	19.9	23.6								
Vancense	000851049	06/27/96	06/27/96	11/22/02	28.4	24.6	23.0	23.4	26.0						
Vancetil	000850736	01/01/82	01/01/91	04/03/07	24.3	23.8	23.1	26.2	24.7	31.5					

Notes: - FDB package sizes for certain NDCs of Proventil and Trilafon were replaced with package sizes derived using implied package sizes from Medspan.

<sup>1</sup> "Spreads" (AWP - AMP) / AMP, were calculated as the weighted average of "spreads", calculated at the 11-digit NDC level, across all accused NDCs within a 9-digit NDC. At the 11-digit NDC level, "spreads" were calculated separately for each period during the calendar year during which neither the AWP nor the AMP had changed. These "spreads" were then aggregated over the calendar year and across 11-digit NDCs using "Gross Sales Activity in the AMP-Related Classes of Trade" (see Note 4).

<sup>2</sup> A 9-digit NDC was considered to be effectively obsolete for a given quarter if its constituent 11-digit NDCs were all declared to be obsolete, discontinued, or converted to over-the-counter products; or if "Gross Sales Activity in the AMP-Related Classes of Trade" had fallen substantially (by 90 percent or more) in anticipation of such events. A 9-digit NDC was considered to be effectively obsolete for a given year if the first 11-digit NDC to be added to the First DataBank (FDB) within the 9-digit NDC was added after June 30th of that year, there were gross sales for less than six months during that year, or the 9-digit NDC was effectively obsolete for at least three quarters of the year. Spreads were not calculated for years during which the 9-digit NDC was effectively obsolete or where the percent of sales or near WAC was not calculated for the reasons indicated in Exhibit 6.

<sup>3</sup> "Branded Products Accused in New York Counties" include all Schering-Plough products listed in Exhibit B to Revised First Amended Consolidated Complaint, with the exception of Cytis-Lutimin NDCs 00085067004 and 00085088711, for which sales data were not available.

<sup>4</sup> "Gross Sales Activity in the AMP-Related Classes of Trade" is defined as Total Gross Sales Activity, limited to the following classes of trade: 111, 121, 123, 171, 172, 341, and 346. Total Gross Sales Activity is defined as direct sales with non-missing credit codes and contract sales from the indirect sales data. Gross sales exclude non-US transactions and transactions with either non-positive revenue or quantity.

Sources: - Schering Sales Data.  
- Medspan Data.  
- First DataBank Data.  
- Exhibit B to Revised First Amended Consolidated Complaint ("City of NY and New York Counties Exhibit B.xls").  
- Schering AMP Data.  
- PRNewswire, "Schering-Plough Aims To Make CLARINEX® As Premier Brand In Prescription Category," March 8, 2002.  
- Schering-Plough Corporation, Form 10-K, for the fiscal year ended December 31, 2001, Item 1.  
- Schering-Plough Corporation, Form 8-K, Exhibit 99.1, "Schering-Plough Reports Sales, Earnings For 2002 Third Quarter," October 24, 2002.